Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

NCT06856577 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)
Wet AMD

Interventions

GENETIC: Ixo-vec
DRUG: Aflibercept

Sponsor

Adverum Biotechnologies, Inc.